Details The technical summary data is suggesting a short of APLS if it tests 36.47 with a downside target of 29.74. We should ...

Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are currently covering the firm, MarketBeat ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report). The company’s shares closed last Friday at $26.68.